Activation of the G protein, Gs, results in increases in cAMP, a necessary step in the pathway for ATP release from rabbit and human erythrocytes. In all cells, the level of cAMP is the product of its synthesis by adenylyl cyclase (AC) and its hydrolysis by phosphodiesterases (PDEs). Both iloprost (ILO), a PGI 2 analog, and isoproterenol (ISO), a β-agonist, stimulate receptor-mediated increases in cAMP in rabbit and human erythrocytes. However, the specific PDEs associated with each of these signaling pathways in the erythrocyte have not been fully characterized. Previously, we reported that PDE3B is present in rabbit and human erythrocyte membranes and that PDE3 inhibitors potentiate ILO-induced increases in cAMP. Here we report that inhibitors of either PDE2 or PDE4, EHNA and rolipram, respectively, potentiate ISO-induced increases in cAMP in rabbit and human erythrocytes. Importantly, these inhibitors had no effect on cAMP increases associated with incubation of erythrocytes with ILO. In addition, we establish, for the first time, the presence of PDE2A protein in rabbit and human erythrocyte membranes. Finally, we determined that incubation of rabbit erythrocytes with EHNA and rolipram together, at concentrations that did not alter ISO-induced increases in cAMP when given alone, potentiate ISO-induced increases in cAMP. These results are consistent with the hypothesis that, in rabbit and human erythrocytes, ILO-induced increases in cAMP are regulated by PDE3 while those associated with ISO are regulated by the activities of both PDE2 and PDE4 and demonstrate that PDE activity in these cells is localized to specific signaling pathways.
INTRODUCTION:
The role of the erythrocyte in the transport of oxygen to meet the metabolic needs of all tissues is well established. In addition to this transport function, it has been shown that when erythrocytes are exposed to mechanical deformation, reduced oxygen tension and some pharmacological stimuli, they release ATP (5, 24, 33, 35, 37) . This erythrocyte-derived ATP can contribute to the control of vascular resistance via activation of purinergic receptors on the endothelium resulting in the local release of vasodilators such as nitric oxide (NO), prostacyclin (PGI 2 ) and hyperpolarizing factors (10, 36) . Two well characterized pharmacological stimuli for ATP release from mammalian erythrocytes are β-receptor agonists and PGI 2 analogs acting via the β-adrenergic (β 2 AR) and PGI 2 receptors (IPR), respectively (25, 30, 34, 41) . Importantly, activation of these G-protein-coupled receptors is associated with increases in intracellular cAMP (33) , a requirement for ATP release from human and rabbit erythrocytes (37) .
It is well established that cAMP is a second messenger in a large number of intracellular signaling pathways (11, 44) . Thus local levels of cAMP in a cell must be tightly regulated. Within the erythrocyte, regulation of the concentration of this second messenger is a critical control point for modulation of ATP release in response to pharmacological stimuli. In all cells, intracellular cAMP levels are the result of the balance between cAMP synthesis by adenylyl cyclases and its hydrolysis by phosphodiesterases (PDEs). Erythrocytes possess PDE activity, however the individual PDE isoforms present and their association with any signaling pathway is less well defined. Previously we reported that, in rabbit and human erythrocytes, PDE3 modulates increases in cAMP associated with IPR activation (13) . However, the PDE(s) involved in the regulation of increases in cAMP associated with activation of the β 2 AR in these cells has not been determined.
In non-erythroid cells, it is well accepted that cAMP generated in response to specific receptor stimulation is compartmentalized and that the PDEs which regulate the increases in cAMP aid in conferring selectivity to the associated cell response (18, 38) . Here we investigate the hypothesis that the PDEs responsible for the regulation of cAMP increases associated with activation of the IPR and the β 2 AR in erythrocytes are distinct.
In the present study we focused on PDEs 2, 3 and 4 because PDE3 activity has been linked with the IPR, whereas the activity of PDE2 and PDE4 have been shown to be associated with β 2 AR in other cell types (8, 12, 21, 28, 31, 43) . We wished to confirm that PDE3 activity is associated with hydrolysis of cAMP generated in response to activation of the IPR, and that this PDE does not modulate cAMP increases resulting from activation of the β 2 AR. In addition, we wished to demonstrate that PDE2 and PDE4 activities contribute to the regulation of cAMP generated in response to activation of the β 2 AR, but not the IPR. Finally, we sought to establish, for the first time, that PDE2 protein is present in rabbit and human erythrocyte membranes.
METHODS:

Isolation of Erythrocytes:
Rabbits were anesthetized with ketamine (12.5 mg/kg) and xylazine (1.5 mg/kg) intramuscularly, followed by pentobarbital sodium (10 mg/kg) administered via a cannula placed in an ear vein. A catheter was placed in a carotid artery and heparin (500 units) was administered. After 10 min, the animals were exsanguinated. Immediately after collection of blood, erythrocytes were isolated by centrifugation at 500 x g at 4°C for 10 min. The supernatant and buffy coat were removed by aspiration. Packed erythrocytes were re-suspended and washed 3 times in a physiological salt solution containing, in mM; (4.7 KCl, 2.0 CaCl 2 , 1.2 MgSO 4 , 140.5 NaCl, 21.0 Tris-base and 5.5 dextrose with 0.5% bovine serum albumin, pH adjusted to 7.4). Erythrocytes were prepared on the day of use. Human blood was obtained by venipuncture using a syringe containing heparin (500 units).
Immediately after collection of blood, erythrocytes were prepared as described above. Protocols for blood collection were approved by the appropriate Saint Louis University committees.
Preparation of Erythrocyte Membranes:
Washed erythrocytes were diluted 1:100 with ice-cold lysis buffer containing 5 mM Tris-HCl, 2 mM EDTA, pH 7.4, and stirred at 4 °C for 20 minutes. The lysate was centrifuged at 23,300 x g for 15 minutes at 4 °C. The supernatant was removed and discarded. The pellet containing the erythrocyte membranes was resuspended and centrifuged two additional times with ice-cold buffer. Membrane protein concentrations were determined using the BCA Protein Assay (Pierce). The final pellet was frozen at -80 °C.
Western Analysis:
Purified erythrocyte membranes were solubilized in SDS buffer (0.277 M SDS, 60% glycerol, 0.25 M Tris-HCl (pH 6.8), 0.004% bromophenol blue, and 0.400 M dithiothreitol), boiled, loaded onto a precast gel (Pierce) and subjected to electrophoresis. The proteins were transferred to a polyvinylidene difluoride (PVDF) membrane in buffer containing 25 mM Tris, 192 mM glycine, and 20% methanol.
Membranes were blocked overnight with 5% non-fat dry milk in PBS containing 0.1% Tween-20 then immunoblotted with a monoclonal mouse antibody directed against amino acids 869-912 in the Nterminus of PDE2A (Affinity Bioreagents) or with a polyclonal goat antibody directed to an internal region of PDE2A (Santa Cruz). The membranes were then incubated with an appropriate secondary antibody in 1% non-fat dry milk and the proteins that were identified were visualized using enhanced chemiluminesence (Pierce).
Incubation of erythrocytes with pharmacological agents:
Washed erythrocytes were diluted to a 50% hematocrit (1 ml) and were preincubated with a PDE inhibitor or its vehicle for 30 minutes. The inhibitors studied were vinpocetine, a selective PDE1 inhibitor (Sigma-Aldrich), 3-isobutyl-1-methylxanthine, a non-selective PDE inhibitor (IBMX, SigmaAldrich), rolipram, a selective PDE4 inhibitor (Tocris), erythro-9-(2-hydroxy-3-nonyl)adenine, EHNA (Biomol), a selective PDE2 inhibitor and cilostazol, a selective PDE3 inhibitor (Sigma-Aldrich). The 6 vehichle for vinpocetine, rolipram and cilostazol was N',N-dimethylformamide (DMF, SigmaAldrich) and the vehicle for EHNA, isoproterenol (ISO, Sigma-Aldrich) and iloprost (ILO, Cayman) was saline. Erythrocytes were then incubated with either (ISO, 1 μM, 30 min) or (ILO, 1 μM, 15 min) in the absence or presence of the various PDE inhibitors. The reaction was stopped with the addition of 4 ml ice-cold acid ethanol containing 1 mM HCl.
Measurement of cAMP:
The erythrocyte-ethanol mixture was centrifuged at 14,000 x g for 10 minutes at 4 °C. The supernatant was removed and stored overnight at -20 °C. Samples were centrifuged a second time at 3,700 x g for 10 minutes at 4 °C. The supernatant was again removed and dried under vacuum centrifugation.
Concentrations of cAMP were determined by EIA (GE Healthcare).
Data Analysis:
Statistical significance was determined using an analysis of variance (ANOVA). In the event that the Fratio indicated a change had occurred, a Fisher's LSD test was performed to identify individual differences. Results were reported as means ± the standard error from the mean (SEM).
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RESULTS:
Effect of the non-selective PDE inhibitor, 3-isobutyl-1-methylxanthine (IBMX), on ILO-and ISO-induced increases in cAMP.
To determine the effect of non-selective inhibition of PDE activity on ILO-and ISO-induced increases in cAMP, rabbit erythrocytes were incubated with each agonist in the absence or presence of IBMX (10 μM). This concentration of IBMX had no effect on baseline cAMP levels. Incubation of rabbit erythrocytes with either ILO (1 μM, n=7) or ISO (1 μM, n=7) in the absence of IBMX resulted in a 141±16 and 172±34 % increase in cAMP, respectively. Pretreatment of erythrocytes with IBMX potentiated the increases in cAMP associated with both ILO (n=7, figure 1A , P<0.01) and ISO (n=7, figure 1B, P<0.01) administration. These data demonstrate that PDE activity is present in rabbit erythrocytes and that it regulates increases in cAMP associated with agonist-induced activation of the IPR and β 2 AR.
Effect of the selective PDE1 inhibitor, vinpocetine, on ILO and ISO-induced increases in cAMP.
To establish that PDE1 is not responsible for the hydrolysis of cAMP generated by activation of the IPR and β 2 AR, rabbit erythrocytes were incubated with either ILO (1 μM, n=8) or ISO (1 μM, n=4) in the absence or presence of the selective PDE1 inhibitor, vinpocetine (30µM). Vinpocetine, at the concentration used, had no effect on basal cAMP levels or on either the ISO-or ILO-induced increases in cAMP (table 1) . The results are consistent with the hypothesis that, PDE1 activity is not associated with the regulation of either ILO-or ISO-induced increases in cAMP in rabbit erythrocytes.
Effect of the selective PDE3 inhibitor, cilostazol, on ILO-and ISO-induced increases in cAMP.
Previously, we identified PDE3B as a component of both rabbit and human erythrocyte membranes.
The selective PDE3 inhibitor, cilostazol (CILO), potentiated the ILO-induced increases in cAMP in these cells (13) . Therefore, to determine if PDE3 is also responsible for modulation of ISO-induced increases in cAMP in rabbit erythrocytes, cells were incubated with ISO (1 μM, n=7) or ILO (1 μM, n=7) in the absence and presence of CILO (10 µM). This concentration of CILO did produce a small, but significant, increase in baseline levels of cAMP from 0.80 ± 0.04 to 0.91 ± 0.04 pmol/10 10 erythrocytes, (P<0.05). In contrast to the results with vinpocetine, ILO-induced increases in cAMP were augmented by CILO (figure 2A, P<0.01); while CILO had no effect on the ISO-induced increases in cAMP (figure 2B). These data suggest that, in rabbit erythrocytes, PDE3 is involved with the regulation of ILO-induced increased in cAMP, but not those associated with activation of the β 2 AR.
Effect of the selective PDE2 inhibitor, EHNA, on ILO-and ISO-induced increases in cAMP.
To determine if PDE2 activity regulates increases in cAMP stimulated by either ISO or ILO, rabbit erythrocytes were incubated with these agonists in the absence or presence of the selective PDE2 inhibitor, EHNA (30 μM). Like cilostazol, EHNA at the concentration used, did produce a small but significant increase in baseline levels of cAMP from 0.80 ± 0.04 to 1.18 ± 0.06 pmol/10 10 erythrocytes, (P<0.01). However, EHNA potentiated cAMP increases produced by ISO (n=8, figure 3A , P<0.01) but had no effect on ILO-induced increases in cAMP (n=7, figure 3B ). These results are consistent with the conclusion that PDE2 activity modulates increases in cAMP produced by ISO but not ILO, in rabbit erythrocytes.
Identification of PDE2 as a component of rabbit and human erythrocyte membranes.
Although the above studies provide strong support for the hypothesis that PDE2 activity regulates increases in cAMP associated with activation of the β 2 AR, they do not establish that PDE2 protein is present in erythrocytes. There are no prior reports that PDE2 is a component of erythrocyte membranes. However, in other cell types, an isoform of PDE2, PDE2A, is found in association with the cell membrane (4, 29) . Therefore, in order to determine if PDE2A protein is present in membranes of rabbit and human erythrocytes, cell membranes were isolated and probed by Western analysis with a monoclonal antibody directed against amino acids 869-912 in the N-terminus of PDE2A or with a polyclonal antibody directed to an internal epitope of PDE2A. Both antibodies identified a band with a predicted molecular weight of ~105 kDa (figure 4A and B) in rabbit and human erythrocytes.
Effect of the selective PDE4 inhibitor, rolipram, on ILO-and ISO-induced increases in cAMP.
In addition to PDE2, PDE4 activity has been associated with the β 2 AR in cardiac myocytes (8, 43) .
Therefore, to determine if PDE4 activity also contributes to the regulation of ISO-induced increases in cAMP in mammalian erythrocytes, rabbit erythrocytes were pre-incubated with the selective PDE4
inhibitor, rolipram (20 µM), prior to the addition of either ISO (1 μM, n=9) or ILO (1 µM, n=7). Rolipram, at this concentration, had no effect on basal cAMP levels but potentiated ISO-induced increases in cAMP ( figure 5A, P<0.05 ). Importantly, rolipram had no effect on ILO-induced increases in cAMP ( figure 5B ). This finding, coupled with the finding that an inhibitor of PDE2 activity potentiates ISOinduced increases in cAMP, is consistent with the hypothesis that both PDE2 and PDE4 contribute to the regulation of cAMP associated with activation of the β 2 AR in rabbit RBCs.
Effect of the combination of rolipram and EHNA on the ISO-induced increases in cAMP.
As reported above, we determined that inhibitors of the activity of either PDE2 or PDE4 results in increases in cAMP associated with incubation of rabbit erythrocytes with ISO. This result, coupled with reports that both PDE2 and PDE4 are associated with the β 2 AR signaling pathway in other cells (21, 22, 43) , suggests that both PDEs participate in the regulation of increases in cAMP associated with activation of the β 2 AR in rabbit erythrocytes. Therefore, to determine if PDE2 and PDE4 act synergistically to hydrolyze increased levels of cAMP associated with activation of the β 2 AR in erythrocytes, we incubated rabbit erythrocytes with the combination of EHNA (10 µM) and rolipram (10 µM) prior to the addition of ISO. The concentrations of the inhibitors used in these studies had no effect on ISO-induced increases in cAMP when administered alone. Moreover, the combination of inhibitors had no effect on basal cAMP levels. However, incubation of rabbit erythrocytes with this combination potentiated ISO-induced increases in cAMP (figure 6, n=9, P<0.05). This finding suggests that ISO-induced increases in cAMP are regulated by the activity of both PDE2 and PDE4 in rabbit erythrocytes.
Effect of selective inhibitors of PDE2 and PDE4 on ISO-induced increases in cAMP in human erythrocytes.
To determine if inhibition of either PDE2 or PDE4 would potentiate the ISO-induced increases in cAMP in human erythrocytes, cells were pre-incubated with either EHNA (30 μM, n=7) or rolipram (20 µM, n=7), prior to the addition of ISO (1 µM). Incubation of RBCs with either inhibitor potentiated the ISOinduced increases in cAMP ( figure 7, P<0.01 ). These results demonstrate that increases in cAMP associated with activation of the β 2 AR in human erythrocytes are regulated by PDEs 2 and 4, as is the case in rabbit erythrocytes.
DISCUSSION:
Rabbit and human erythrocytes possess PDE activity that is associated with the hydrolysis of cAMP (1). This conclusion was reached based on the finding that incubation of erythrocytes with the non-selective PDE inhibitor, IBMX, results in increases in cAMP. However, the specific PDEs present in mammalian erythrocytes were not defined nor was their activity associated with any discrete signaling pathway. Recently, we reported that PDE3B is present in rabbit and human erythrocyte membranes and that this PDE is responsible for hydrolysis of cAMP generated by incubation of erythrocytes with the active PGI 2 analog, iloprost (ILO) (13, 34) . In the present study, we demonstrate pharmacologically that PDE2 and PDE4 activities are also present in rabbit and human erythrocytes.
In addition, using Western analysis, we establish for the first time that PDE2 protein is also a component of the membranes of these cells. In addition, we determined that increases in cAMP produced by the β-agonist, isoproterenol (ISO), are regulated by the activity of PDEs 2 and 4 in both rabbit and human erythrocytes.
PDEs are ubiquitously expressed in mammalian tissues and because of their ability to hydrolyze cyclic nucleotides, they play a major role in the regulation of many signal transduction pathways.
Currently 11 distinct PDE enzyme families have been characterized based on gene product, biochemical properties, mode of regulation, sensitivity to pharmacological agents and their specificity for hydrolysis of cAMP, cGMP or, in some cases, both cyclic nucleotides (4, 16, 18).
The presence of differentially regulated PDE isoforms within cells that are associated with discrete signaling pathways allows for subcellular regulation of cAMP levels. This tight regulation of local cAMP concentration within a cell permits the precise regulation of cellular responses to external stimuli (7, 15, 26, 32) . In non-erythroid cells, distinct PDEs are associated with G-protein-coupled receptor signaling pathways and thereby, contribute to compartmentalization of cAMP signaling (32, 39, 42) . For example, there is evidence for involvement of PDEs 2 and 4 in the regulation of increases in cAMP resulting from activation of the β 2 AR in cardiac myocytes (8, 21, 22, 43) . In contrast, increases in cAMP associated with activation of the IPR were reported to be regulated by the activity of PDE3 in platelets and the pulmonary vasculature (12, 20, 28, 31) . A functional role for PDE3 in rabbit and human erythrocytes was demonstrated by the finding that selective inhibitors of PDE3 augmented increases in cAMP associated with agonist-induced activation of the IPR in these cells (13) . Here, we confirm that finding (figure 2) in rabbit erythrocytes and establish that selective inhibitors of the activity of PDEs 2 and 4 do not augment increases in cAMP associated with activation of the IPR in these cells ( figures 3 and 4) .
The only other PDE activity previously reported to be present in mammalian erythrocytes is that of PDE1 (27) . However, this PDE was reported to hydrolyze cGMP and the effect of PDE1 activity on cAMP levels in erythrocytes was not investigated. Importantly, PDE1 activity was not reported to be associated with any signaling pathway (27) . Previously, we reported that the selective inhibitor of PDE1 activity, vinpocetine, did not potentiate increases in cAMP associated with activation of the IPR in human erythrocytes (13) . Here, we demonstrate that vinpocetine has no effect on cAMP increases resulting from receptor-mediated activation of either the IPR or the β 2 AR signaling pathways in rabbit erythrocytes (Table 1) . These results suggest that increases in cAMP produced by activation of the IPR or β 2 AR are regulated by PDEs other than PDE1 in both rabbit and human erythrocytes.
In addition to PDEs 1 and 3, we have determined for the first time that PDE2 is a component of the membranes of rabbit and human erythrocytes ( figure 5 ). EHNA, a selective inhibitor of PDE2, did not augment increases in cAMP associated with receptor-mediated activation of the IPR in rabbit erythrocytes ( figure 3A) . Importantly, EHNA did potentiate increases in cAMP associated with incubation of both rabbit and human erythrocytes with the β 2 AR agonist, ISO ( figure 3B and 7) . Taken together, these results provide support for the hypothesis that PDE2 participates in the regulation of increases in cAMP associated with β 2 AR activation but not with increases in cAMP associated with the IPR signaling pathway in rabbit and human erythrocytes.
It is well established that, in other cell types, PDE4 is also associated with regulation of increases in cAMP produced by activation of the β 2 AR (8, 43) . Here, we used the selective PDE4
inhibitor, rolipram, to determine if PDE4 activity also contributes to the regulation of the increases in cAMP associated with β 2 AR activation in rabbit and human erythrocytes. Rolipram potentiated the increases in cAMP associated with isoproterenol-induced β 2 AR activation in erythrocytes of both species ( Figures 4B and 7) . Importantly, in rabbit erythrocytes, rolipram had no effect on increases in cAMP associated with incubation of these cells with the IPR agonist, iloprost ( Figure 4A ). In contrast to PDE3B and PDE2A, most PDE4 isoforms are located in the cytosol (2, 14, 26) . The identification of a cytosolic isoform of PDE4 in erythrocytes is complicated by the presence of large amounts of hemoglobin in this cell. Although we do not report the presence of PDE4 protein in rabbit or human erythrocytes in this study, this does not diminish the importance of our finding that the selective inhibitor of PDE4, rolipram, potentiated increases in cAMP associated with activation of the β 2 AR while having no effect on IPR-associated increases in cAMP in these erythrocytes (figure 4).
The results of studies with EHNA and rolipram provide strong evidence that PDE2 and PDE4
are both involved in the hydrolysis of cAMP generated in response to receptor-mediated activation of the β 2 AR in rabbit and human erythrocytes and not the IPR. Therefore, it was of interest to determine if PDE2 and PDE4 act synergistically in the regulation of β 2 AR-mediated increases in cAMP in erythrocytes. When rabbit erythrocytes were incubated with concentrations of EHNA and rolipram that alone had no effect on ISO-induced increases in cAMP we observed a significant augmentation of ISOinduced increases cAMP ( Figure 6 ) suggesting that both PDEs are actively involved in regulation of increases in cAMP generated in response to receptor-mediated activation of the β 2 AR in rabbit erythrocytes. The proposed relationships among PDEs 2, 3 and 4 and their association with the β 2 AR and IPR in rabbit and human erythrocytes are depicted in figure 8 .
It is important to note that, at the concentrations used in these studies, the PDE inhibitors used are considered to be selective for the targeted PDE (16, 18, 40) and are based on published IC 50 values (3, 4, 6) . In addition, concentrations of IBMX (10 µM), vinpocetine (30 μM) and rolipram (20μM) were chosen to have no effect on basal cAMP levels. Although EHNA (30μM) and cilostazol (10μM) did produce small increases in baseline cAMP levels, these inhibitors had no effect on increases in cAMP in cells incubated with either ILO or ISO, respectively (Figures 2 and 3 ).
Under in vivo conditions, vessels are perfused with blood containing erythrocytes. It is well established that both ISO and prostacyclin analogues, including ILO, produce vasodilation when administered therapeutically. Although each clearly has direct effects on vascular smooth muscle, we suggest that these agonists can additionally interact with receptors on erythrocytes leading to the release of ATP (25, 33, 34), a potent stimulus for the synthesis of endothelium-derived vasodilators.
Therefore, it is possible that intravenously administered ISO or ILO could also interact with circulating erythrocytes contributing to the associated vasodilation. In addition, since PDEs are now becoming important therapeutic targets in the treatment of pulmonary hypertension and peripheral vascular disease (16, 18, 40) , identification of the individual PDEs that regulate cAMP accumulation associated with activation of the β 2 AR and IPR signaling pathways in erythrocytes could provide new therapeutic targets for the development of drugs for the treatment of these conditions.
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